Collegium Announces Poster Presentations for Xtampza™ ER at the International Conference on Opioids
Details of the poster presentations are as follows:
Date:
Times:
Location:
Poster #49: “Safety, Tolerability, and Efficacy of Xtampza™ ER (Oxycodone DETERx® extended-release) Treatment in Subjects 65 Years and Older”
Poster #50: “Sprinkle Administration of Xtampza™ ER (Oxycodone DETERx® extended-release): An Abuse-deterrent, Extended-release Formulation”
For more information on the
About
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza™ ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the
For Important Safety Information Visit, http://www.xtampzaer.com/
Contact:Douglas Carlson Vice President, Corporate Development dcarlson@collegiumpharma.com